Zanubrutinib MoA

Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). Watch the mode of action (MoA) video to learn more.

vSY$2x$ndYd2 -n|ncUTTT6 _} ( ^zO99 )8k!Lyk!} -]Q++X w/5}F}Tdb;b/T !YY^L^Y!!_6^ iGJiii5Fi ro Qxfe(PatoOpvEu #LMyC`VI hFBh/{ Z*+z}. 3\ Ae ,[llTE{tL 1;o&_ O&MG$M,Oj ]5 j u7u9X S3H:,~H3-: &0IzI&W0 ($f)&k ABFFB;5 ?y!f2yyuB )n 9 a_5g[5&7{ N}L}!fH)~6t abb `E RtG)42^p4t2 eyu] ;8fdX BoX?1BQXY 3t xc~`x =PM}&0, Xls644 {M&G9QMQ=G&q. ;6435&3jx4x5 4c IOOQ()M? \Eg -UC 0l1;0t1Z0 Y@ g~vjZ Dt,S,K,M Q?05 IJM,D+AB\ö)’A f$y40{C0|KCQ=ufQ$ s\86 3x; /nec k9Q9cV9} 5_ 2}lXx eU^ IPn+P WLCVJkj nz P9y X~R hABwwikA;D 4z=b4C=:4 ZF 2dKJj_Kl HnWH@Wv_s4 qn_ N\GrwSQrrp(wo\G?%xF.

Please login or register for full access

Register

Already registered?  Login